Synergistic cooperation between sunitinib and cisplatin promotes apoptotic cell death in human medullary thyroid cancer

Alessia Lopergolo, Valentina Nicolini, Enrica Favini, Laura Dal Bo, Monica Tortoreto, Denis Cominetti, Marco Folini, Paola Perego, Vittoria Castiglioni, Eugenio Scanziani, Maria Grazia Borrello, Nadia Zaffaroni, Giuliana Cassinelli, Cinzia Lanzi

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Context: Tyrosine kinase inhibitors represent a new treatment option for patients with advanced medullary thyroid cancer (MTC). However, cures have not been achieved with current available agents used in monotherapy. Objective: Because RET has been shown to negatively regulate CD95 death receptor activation in preclinical models of RET-dependent MTC, we investigated the potential of the combination approach with the RET-targeting tyrosine kinase inhibitor sunitinib and cisplatin to enhance apoptosis activation through the extrinsic pathway. Design: The effects of sunitinib and cisplatin were examined in human MTC cell lines harboring oncogenic RET mutations. Experiments were designed to determine drug effects on RET signaling, cell growth, apoptosis, autophagy, and tumor growth in mice and to investigate the mechanisms of the drug interaction. Results: Sunitinib and cisplatin synergistically inhibited the growth of MZ-CRC-1 cells harboring the RET M918T activating mutation. The combination enhanced apoptosis activation through CD95- mediated, caspase-8-dependent pathway. Moreover, sunitinib induced a severe perturbation of the autophagic flux characterized by autophagosome accumulation and a remarkable lysosomal dysfunction, which was further enhanced, with lysosomal leakage induction, by cisplatin. Administration of the drug combination to mice xenografted withMZ-CRC-1cells improved the antitumor efficacy, as compared with single-agent treatments, inducing complete responses in 30% of the treated mice, a significant increase in caspase-3 activation (P <.01 vs cisplatin, and P <.0005 vs sunitinib) and apoptosis in tumor cells. Conclusions: Addition of cisplatin to sunitinib potentiates apoptotic cell death and has promising preclinical activity in MTCs harboring the RET M918T oncogene.

Original languageEnglish
Pages (from-to)498-509
Number of pages12
JournalJournal of Clinical Endocrinology and Metabolism
Volume99
Issue number2
DOIs
Publication statusPublished - Feb 2014

Fingerprint

Cell death
Cisplatin
Cell Death
Chemical activation
Apoptosis
Protein-Tyrosine Kinases
Tumors
Growth
Cells
Drug interactions
Death Domain Receptors
Mutation
Caspase 8
Autophagy
Cell growth
Drug Combinations
Drug Interactions
Oncogenes
Caspase 3
sunitinib

ASJC Scopus subject areas

  • Biochemistry
  • Clinical Biochemistry
  • Endocrinology
  • Biochemistry, medical
  • Endocrinology, Diabetes and Metabolism

Cite this

Synergistic cooperation between sunitinib and cisplatin promotes apoptotic cell death in human medullary thyroid cancer. / Lopergolo, Alessia; Nicolini, Valentina; Favini, Enrica; Bo, Laura Dal; Tortoreto, Monica; Cominetti, Denis; Folini, Marco; Perego, Paola; Castiglioni, Vittoria; Scanziani, Eugenio; Borrello, Maria Grazia; Zaffaroni, Nadia; Cassinelli, Giuliana; Lanzi, Cinzia.

In: Journal of Clinical Endocrinology and Metabolism, Vol. 99, No. 2, 02.2014, p. 498-509.

Research output: Contribution to journalArticle

Lopergolo, Alessia ; Nicolini, Valentina ; Favini, Enrica ; Bo, Laura Dal ; Tortoreto, Monica ; Cominetti, Denis ; Folini, Marco ; Perego, Paola ; Castiglioni, Vittoria ; Scanziani, Eugenio ; Borrello, Maria Grazia ; Zaffaroni, Nadia ; Cassinelli, Giuliana ; Lanzi, Cinzia. / Synergistic cooperation between sunitinib and cisplatin promotes apoptotic cell death in human medullary thyroid cancer. In: Journal of Clinical Endocrinology and Metabolism. 2014 ; Vol. 99, No. 2. pp. 498-509.
@article{032dbde7f5394ee6aaa2e64a0dd5f80c,
title = "Synergistic cooperation between sunitinib and cisplatin promotes apoptotic cell death in human medullary thyroid cancer",
abstract = "Context: Tyrosine kinase inhibitors represent a new treatment option for patients with advanced medullary thyroid cancer (MTC). However, cures have not been achieved with current available agents used in monotherapy. Objective: Because RET has been shown to negatively regulate CD95 death receptor activation in preclinical models of RET-dependent MTC, we investigated the potential of the combination approach with the RET-targeting tyrosine kinase inhibitor sunitinib and cisplatin to enhance apoptosis activation through the extrinsic pathway. Design: The effects of sunitinib and cisplatin were examined in human MTC cell lines harboring oncogenic RET mutations. Experiments were designed to determine drug effects on RET signaling, cell growth, apoptosis, autophagy, and tumor growth in mice and to investigate the mechanisms of the drug interaction. Results: Sunitinib and cisplatin synergistically inhibited the growth of MZ-CRC-1 cells harboring the RET M918T activating mutation. The combination enhanced apoptosis activation through CD95- mediated, caspase-8-dependent pathway. Moreover, sunitinib induced a severe perturbation of the autophagic flux characterized by autophagosome accumulation and a remarkable lysosomal dysfunction, which was further enhanced, with lysosomal leakage induction, by cisplatin. Administration of the drug combination to mice xenografted withMZ-CRC-1cells improved the antitumor efficacy, as compared with single-agent treatments, inducing complete responses in 30{\%} of the treated mice, a significant increase in caspase-3 activation (P <.01 vs cisplatin, and P <.0005 vs sunitinib) and apoptosis in tumor cells. Conclusions: Addition of cisplatin to sunitinib potentiates apoptotic cell death and has promising preclinical activity in MTCs harboring the RET M918T oncogene.",
author = "Alessia Lopergolo and Valentina Nicolini and Enrica Favini and Bo, {Laura Dal} and Monica Tortoreto and Denis Cominetti and Marco Folini and Paola Perego and Vittoria Castiglioni and Eugenio Scanziani and Borrello, {Maria Grazia} and Nadia Zaffaroni and Giuliana Cassinelli and Cinzia Lanzi",
year = "2014",
month = "2",
doi = "10.1210/jc.2013-2574",
language = "English",
volume = "99",
pages = "498--509",
journal = "Journal of Clinical Endocrinology and Metabolism",
issn = "0021-972X",
publisher = "The Endocrine Society",
number = "2",

}

TY - JOUR

T1 - Synergistic cooperation between sunitinib and cisplatin promotes apoptotic cell death in human medullary thyroid cancer

AU - Lopergolo, Alessia

AU - Nicolini, Valentina

AU - Favini, Enrica

AU - Bo, Laura Dal

AU - Tortoreto, Monica

AU - Cominetti, Denis

AU - Folini, Marco

AU - Perego, Paola

AU - Castiglioni, Vittoria

AU - Scanziani, Eugenio

AU - Borrello, Maria Grazia

AU - Zaffaroni, Nadia

AU - Cassinelli, Giuliana

AU - Lanzi, Cinzia

PY - 2014/2

Y1 - 2014/2

N2 - Context: Tyrosine kinase inhibitors represent a new treatment option for patients with advanced medullary thyroid cancer (MTC). However, cures have not been achieved with current available agents used in monotherapy. Objective: Because RET has been shown to negatively regulate CD95 death receptor activation in preclinical models of RET-dependent MTC, we investigated the potential of the combination approach with the RET-targeting tyrosine kinase inhibitor sunitinib and cisplatin to enhance apoptosis activation through the extrinsic pathway. Design: The effects of sunitinib and cisplatin were examined in human MTC cell lines harboring oncogenic RET mutations. Experiments were designed to determine drug effects on RET signaling, cell growth, apoptosis, autophagy, and tumor growth in mice and to investigate the mechanisms of the drug interaction. Results: Sunitinib and cisplatin synergistically inhibited the growth of MZ-CRC-1 cells harboring the RET M918T activating mutation. The combination enhanced apoptosis activation through CD95- mediated, caspase-8-dependent pathway. Moreover, sunitinib induced a severe perturbation of the autophagic flux characterized by autophagosome accumulation and a remarkable lysosomal dysfunction, which was further enhanced, with lysosomal leakage induction, by cisplatin. Administration of the drug combination to mice xenografted withMZ-CRC-1cells improved the antitumor efficacy, as compared with single-agent treatments, inducing complete responses in 30% of the treated mice, a significant increase in caspase-3 activation (P <.01 vs cisplatin, and P <.0005 vs sunitinib) and apoptosis in tumor cells. Conclusions: Addition of cisplatin to sunitinib potentiates apoptotic cell death and has promising preclinical activity in MTCs harboring the RET M918T oncogene.

AB - Context: Tyrosine kinase inhibitors represent a new treatment option for patients with advanced medullary thyroid cancer (MTC). However, cures have not been achieved with current available agents used in monotherapy. Objective: Because RET has been shown to negatively regulate CD95 death receptor activation in preclinical models of RET-dependent MTC, we investigated the potential of the combination approach with the RET-targeting tyrosine kinase inhibitor sunitinib and cisplatin to enhance apoptosis activation through the extrinsic pathway. Design: The effects of sunitinib and cisplatin were examined in human MTC cell lines harboring oncogenic RET mutations. Experiments were designed to determine drug effects on RET signaling, cell growth, apoptosis, autophagy, and tumor growth in mice and to investigate the mechanisms of the drug interaction. Results: Sunitinib and cisplatin synergistically inhibited the growth of MZ-CRC-1 cells harboring the RET M918T activating mutation. The combination enhanced apoptosis activation through CD95- mediated, caspase-8-dependent pathway. Moreover, sunitinib induced a severe perturbation of the autophagic flux characterized by autophagosome accumulation and a remarkable lysosomal dysfunction, which was further enhanced, with lysosomal leakage induction, by cisplatin. Administration of the drug combination to mice xenografted withMZ-CRC-1cells improved the antitumor efficacy, as compared with single-agent treatments, inducing complete responses in 30% of the treated mice, a significant increase in caspase-3 activation (P <.01 vs cisplatin, and P <.0005 vs sunitinib) and apoptosis in tumor cells. Conclusions: Addition of cisplatin to sunitinib potentiates apoptotic cell death and has promising preclinical activity in MTCs harboring the RET M918T oncogene.

UR - http://www.scopus.com/inward/record.url?scp=84893789057&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84893789057&partnerID=8YFLogxK

U2 - 10.1210/jc.2013-2574

DO - 10.1210/jc.2013-2574

M3 - Article

C2 - 24276455

AN - SCOPUS:84893789057

VL - 99

SP - 498

EP - 509

JO - Journal of Clinical Endocrinology and Metabolism

JF - Journal of Clinical Endocrinology and Metabolism

SN - 0021-972X

IS - 2

ER -